Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT02654483
A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients
Professor of Dermatology
Clinical Associate Professor, Dermatology
Inclusion Criteria:
- Clinical diagnosis of Epidermolysis Bullosa (EB) and pruritus
Exclusion Criteria:
- Chronic liver or renal disease
drug: VPD-737
drug: VPD-737
other: Placebo
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Claudia Teng
725-7152